THRIVE Drug Patent Profile
✉ Email this page to a colleague
When do Thrive patents expire, and when can generic versions of Thrive launch?
Thrive is a drug marketed by Glaxosmithkline Cons and is included in two NDAs.
The generic ingredient in THRIVE is nicotine polacrilex. There are thirty drug master file entries for this compound. Fifty-nine suppliers are listed for this compound. Additional details are available on the nicotine polacrilex profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Thrive
A generic version of THRIVE was approved as nicotine polacrilex by P AND L on March 15th, 1999.
Summary for THRIVE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 2 |
Clinical Trials: | 45 |
Formulation / Manufacturing: | see details |
DailyMed Link: | THRIVE at DailyMed |
Recent Clinical Trials for THRIVE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Imperial College London | Phase 4 |
Vir Biotechnology, Inc. | Phase 1/Phase 2 |
Saint Francis Memorial Hospital | Phase 1 |
Anatomical Therapeutic Chemical (ATC) Classes for THRIVE
US Patents and Regulatory Information for THRIVE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Glaxosmithkline Cons | THRIVE | nicotine polacrilex | GUM, CHEWING;BUCCAL | 077658-001 | Jun 19, 2007 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Glaxosmithkline Cons | THRIVE | nicotine polacrilex | GUM, CHEWING;BUCCAL | 077656-001 | Jun 19, 2007 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |